^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/28/2021
Excerpt:
Medical treatment for advanced/metastatic papillary RCC...Alternative options include sunitinib [II, B], pembrolizumab [III, B] without additional molecular testing and savolitinib (where available) in MET-driven tumours [III, C].
